211,127 Shares in Praxis Precision Medicines, Inc. $PRAX Acquired by GW&K Investment Management LLC

GW&K Investment Management LLC acquired a new stake in Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 211,127 shares of the company’s stock, valued at approximately $61,488,000. GW&K Investment Management LLC owned about 0.76% of Praxis Precision Medicines as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. GAMMA Investing LLC grew its holdings in shares of Praxis Precision Medicines by 10.3% in the second quarter. GAMMA Investing LLC now owns 332 shares of the company’s stock worth $111,000 after purchasing an additional 31 shares during the last quarter. KBC Group NV increased its stake in shares of Praxis Precision Medicines by 5.8% in the first quarter. KBC Group NV now owns 715 shares of the company’s stock worth $230,000 after buying an additional 39 shares during the period. Nisa Investment Advisors LLC raised its holdings in Praxis Precision Medicines by 0.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 6,167 shares of the company’s stock valued at $1,796,000 after buying an additional 56 shares during the last quarter. Ieq Capital LLC raised its holdings in Praxis Precision Medicines by 11.5% during the 3rd quarter. Ieq Capital LLC now owns 909 shares of the company’s stock valued at $265,000 after buying an additional 94 shares during the last quarter. Finally, Eagle Bay Advisors LLC raised its holdings in Praxis Precision Medicines by 11.3% during the 3rd quarter. Eagle Bay Advisors LLC now owns 1,064 shares of the company’s stock valued at $310,000 after buying an additional 108 shares during the last quarter. Hedge funds and other institutional investors own 67.84% of the company’s stock.

Wall Street Analyst Weigh In

PRAX has been the subject of several analyst reports. Robert W. Baird increased their price target on shares of Praxis Precision Medicines from $514.00 to $568.00 and gave the company an “outperform” rating in a research report on Monday. The Goldman Sachs Group restated a “buy” rating and issued a $575.00 price objective (up from $470.00) on shares of Praxis Precision Medicines in a research report on Friday, August 21st. BTIG Research reaffirmed a “buy” rating and set a $826.00 price objective on shares of Praxis Precision Medicines in a research note on Monday, November 9th. Wells Fargo & Company set a $509.00 price objective on shares of Praxis Precision Medicines and gave the company an “overweight” rating in a research note on Tuesday. Finally, Royal Bank Of Canada increased their target price on shares of Praxis Precision Medicines from $462.00 to $478.00 and gave the stock an “outperform” rating in a report on Tuesday, November 10th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Praxis Precision Medicines currently has a consensus rating of “Moderate Buy” and an average price target of $656.42.

Read Our Latest Stock Analysis on PRAX

Praxis Precision Medicines Trading Up 1.9%

Shares of PRAX stock opened at $310.90 on Friday. Praxis Precision Medicines, Inc. has a 12 month low of $160.11 and a 12 month high of $392.70. The stock has a market cap of $8.69 billion, a PE ratio of -24.29 and a beta of 2.85. The company’s fifty day moving average price is $286.77 and its 200-day moving average price is $314.30.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its earnings results on Monday, November 9th. The company reported ($3.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($3.54) by $0.31. On average, sell-side analysts forecast that Praxis Precision Medicines, Inc. will post -13.72 earnings per share for the current fiscal year.

Praxis Precision Medicines Profile

(Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Further Reading

Institutional Ownership by Quarter for Praxis Precision Medicines (NASDAQ:PRAX)

Receive News & Ratings for Praxis Precision Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Praxis Precision Medicines and related companies with MarketBeat.com's FREE daily email newsletter.